HLF · Herbalife Ltd. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on HLF. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About HLF · Herbalife Ltd.
Herbalife Ltd., together with its subsidiaries, provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers weight management products, including meal replacement, protein shakes, drink mixes, weight loss supplements, healthy snacks, and metabolism boosting teas; targeted nutrition products comprising functional beverages and dietary and nutritional supplements containing herbs, vitamins, minerals and other natural ingredients; energy, sports, and fitness products; and facial skin care, body care, and hair care products. The company also provides literature, promotional, and other materials, such as start-up kits, sales tools, and educational materials. It sells its products through sales representatives, independent service providers, and company-operated retail stores and platforms. The company was formerly known as Herbalife Nutrition Ltd. and changed its name to Herbalife Ltd. in April 2023. Herbalife Ltd. was founded in 1980 and is headquartered in Los Angeles, California.
Live Quote
HOLD (score -1) · 12-1 mom 51.3% · RSI 47.9 · below_both · -38.6% from high
Targets blend Wall Street consensus (3 analysts: low $9.00 / mean $18.33 / high $25.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The Form 4 cluster trigger (11 filings in 14 days) consisted entirely of routine RSU vestings with $0 exercise prices (code F — tax withholding only, not open-market buys) and one significant insider SALE by CCO Frank Lamberti totaling ~$1.96M on May 11-12 at then-market prices of $13.50-$13.86. No CEO/CFO open-market purchase was verified. The stock is deeply oversold (RSI 34, -33% from 52-week high of $20), cheaply valued at 4.35x forward P/E with ~7.8% FCF yield, but has no identifiable near-term catalyst beyond August earnings. Q1 beat guidance by +5.4% on EPS; refinancing completed April 29 for $1.45B (7.75% senior secured notes due 2033) extends debt maturity. No smart-money conviction, bearish options flow bias (-$2,418 net put notional), and China regulatory risk remain persistent concerns. The setup is technically oversold but fundamentally uninspiring with no edge the market missed.